We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+8.78%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$1.38B
AUM Growth
-$236M
Cap. Flow
-$330M
Cap. Flow %
-23.99%
Top 10 Hldgs %
54.43%
Holding
96
New
13
Increased
16
Reduced
18
Closed
30

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$35.4M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$22.4M
3
BDX icon
Becton Dickinson
BDX
+$21.2M
4
BBIO icon
BridgeBio Pharma
BBIO
+$20.8M
5
OM icon
Outset Medical
OM
+$20.1M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$25.6M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$22.8M
3
IJH icon
iShares Core S&P Mid-Cap ETF
IJH
+$21.7M
4
LLY icon
Eli Lilly
LLY
+$20.7M
5
UNH icon
UnitedHealth
UNH
+$20.3M

Sector Composition

Rank Sector Weight
1 Healthcare 91.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRBU icon
51
Caribou Biosciences
CRBU
$163M
$2.29M 0.17%
2,506,435
-1,370,027
-35% -$1.78M
SGMT icon
52
Sagimet Biosciences
SGMT
$540M
$2.12M 0.15%
649,006
– –
CAPR icon
53
Capricor Therapeutics
CAPR
$242M
$1.34M 0.1%
140,681
+86,324
+159% +$1.2M
CMPS
54
Compass Pathways
CMPS
$1.83B
$1.29M 0.09%
451,267
– –
MGX icon
55
Metagenomi Therapeutics
MGX
$46.7M
$1.2M 0.09%
885,803
– –
SWTX
56
DELISTED
SpringWorks Therapeutics
SWTX
$1.17M 0.08%
+26,437
New +$1.22M
KROS icon
57
Keros Therapeutics
KROS
$211M
$1.06M 0.08%
104,323
– –
ACLX
58
DELISTED
Arcellx
ACLX
$1.02M 0.07%
15,488
-41,115
-73% -$2.79M
VERV
59
DELISTED
Verve Therapeutics
VERV
$711K 0.05%
155,495
+29,496
+23% +$198K
GPCR icon
60
Structure Therapeutics
GPCR
$3.74B
$699K 0.05%
+40,400
New +$990K
CELC icon
61
Celcuity
CELC
$4.55B
$539K 0.04%
53,349
-105,397
-66% -$1.19M
IOVA icon
62
Iovance Biotherapeutics
IOVA
$2.77B
$440K 0.03%
132,152
– –
TSBX
63
DELISTED
Turnstone Biologics
TSBX
$382K 0.03%
932,348
– –
BOLD
64
Boundless Bio
BOLD
$63.8M
$363K 0.03%
240,513
– –
ADAP
65
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-4,871,969
Closed -$2.62M
ALKS icon
66
Alkermes
ALKS
$8.11B
– –
-80,719
Closed -$2.32M
BBIO icon
67
CALL
BridgeBio Pharma
BBIO
$16.2B
– –
-50,000
Closed -$1.37M
BLUE
68
DELISTED
bluebird bio
BLUE
– –
-75,758
Closed -$632K
BNTX icon
69
BioNTech
BNTX
$22.9B
– –
-33,109
Closed -$3.77M
CAH icon
70
Cardinal Health
CAH
$55.7B
– –
-148,173
Closed -$17.5M
DXCM icon
71
DexCom
DXCM
$31.3B
– –
-328,763
Closed -$25.6M
EW icon
72
CALL
Edwards Lifesciences
EW
$51.5B
– –
-525,400
Closed -$38.9M
GBIO
73
DELISTED
Generation Bio
GBIO
– –
-78,791
Closed -$835K
IEF icon
74
PUT
iShares 7-10 Year Treasury Bond ETF
IEF
$47.2B
– –
-1,000,000
Closed -$92.5M
IJH icon
75
iShares Core S&P Mid-Cap ETF
IJH
$125B
– –
-347,637
Closed -$21.7M
1 2
3
4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
PWA
Pitcairn Wealth Advisors Conshohocken, Pennsylvania $1.09B AUM

PFM Health Sciences's Q1 2025 Portfolio in Review

As of Q1 2025, PFM Health Sciences held 96 positions worth $1.38B, down 15% from $1.61B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

PFM Health Sciences withdrew a net $330M in Q1 2025, closing 30 positions and reducing 18 holdings. Its most notable exit was DexCom, an estimated $25.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 75% a quarter earlier.

Against the trend, PFM Health Sciences opened a new position in Elevance Health worth $38.4M.

  • PFM Health Sciences's largest Q1 2025 buy was Elevance Health: 88,222 shares worth $38.4M.
  • PFM Health Sciences added most to BridgeBio Pharma in Q1 2025, an estimated $20.8M increase.
  • PFM Health Sciences's biggest Q1 2025 reduction was Eli Lilly, cutting an estimated $20.7M.
  • PFM Health Sciences fully exited DexCom in Q1 2025, selling an estimated $25.6M.
  • PFM Health Sciences's ten largest holdings make up 54% of its $1.38B portfolio in Q1 2025.
  • PFM Health Sciences opened 13 new positions and closed 30 in Q1 2025.
  • PFM Health Sciences's portfolio value fell 15% quarter-over-quarter to $1.38B.

Based on PFM Health Sciences's 13F filing for Q1 2025, filed 15 May 2025.